Ekso Bionics Holdings, Inc. (EKSO)
NASDAQ (CM) NASDAQ (CM) Primary 
Why Is Ekso Bionics (EKSO) Stock Down 15% Today?
Ekso Bionics (NASDAQ: EKSO ) stock is taking a beating on Tuesday following the release of the exoskeleton company's Q2 earnings report. The bad news for Ekso Bionics starts with its diluted earnings per share of -13 cents.
Ekso Bionics Holdings, Inc. (EKSO) Q2 2024 Earnings Call Transcript
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q2 2024 Earnings Conference Call July 29, 2024 4:30 PM ET Company Participants Matt Steinberg - Finn Partners Scott Davis - Chief Executive Officer Jerome Wong - Chief Financial Officer Conference Call Participants Ben Haynor - Lake Street Capital Markets Li Chen - H.C. Wainwright Operator Greetings, and welcome to the Ekso Bionics' Q2 2024 Financial Results Call.
Ekso Bionics (EKSO) Reports Q2 Loss, Lags Revenue Estimates
Ekso Bionics (EKSO) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.31 per share a year ago.
Ekso Bionics' (EKSO) New Partnership to Aid Its Ekso Devices
Ekso Bionics (EKSO) announces a research partnership with Shepherd Center to create training and research programs for the Ekso devices.
All You Need to Know About Ekso Bionics (EKSO) Rating Upgrade to Buy
Ekso Bionics (EKSO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
